To ask the Secretary of State for Health and Social Care, when he expects the Prostate Cancer UK-led Transform screening trial to reach any conclusions on future detection of the condition.
Answered on
23 April 2025
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year in research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer as the largest area of spend, at over £133 million in 2023/24, reflecting its high priority. The NIHR funds research and research infrastructure, which supports patients and the public to participate in high-quality research, including clinical research on prostate cancer.
These investments are pivotal towards efforts to improve cancer prevention, treatment, and outcomes. The TRANSFORM trial is an important example of this. On 19 November, the Government and Prostate Cancer UK (PCUK) announced the £42 million TRANSFORM screening trial, to find the best way to screen men for prostate cancer in order to find it before it becomes advanced and harder to treat. PCUK is leading the development of the trial, with the Government contributing £16 million through the Department.
The first recruits to the trial are currently being invited to take part in the study, and the first point at which we will see significant new evidence will be approximately three years after the trial begins. The PCUK website outlines the interim points over the course of the TRANSFORM trial when findings will be shared, with further information available at the following link: